Poster Presentation on Pre-clinical Research of CAP-2003 in Disease Model of Duchenne Muscular Dystrophy
LOS ANGELES, June 28, 2018 (GLOBE NEWSWIRE) — Capricor Therapeutics’ (NASDAQ:CAPR) chief medical officer, Deborah Ascheim, M.D., will present a corporate overview at the Parents Project Muscular Dystrophy (PPMD) 2018 Annual Conference on June 29 in Scottsdale, AZ.
PPMD 2018 Annual Conference
Date: Friday, June 29, 2018
Time: 3:20-3:40 p.m. MST
Location: The Phoenician Hotel, 6000 East Camelback Rd., Scottsdale, AZ 85251
Capricor will also provide a poster presentation that will report pre-clinical data demonstrating the immunomodulatory capability of the company’s exosome product, CAP-2003, and the ability of this product to improve exercise capabilities in mdx mice after systemic administration.
“The poster presentation highlights the immunomodulatory properties of CAP-2003 in treating Duchenne muscular dystrophy, a disease of severe inflammation,” said Linda Marbán, Ph.D., Capricor president and chief executive officer. “The improvements noted in exercise capability substantiates that exosomes are the mechanism of action in our cellular therapies.”
To see the corporate overview via a webcast, please visit: https://www.youtube.com/watch?v=iMpPPx8aETU
The webcast will be archived for approximately 30 days and will be available at http://capricor.com/news/events/.
The poster presented at the PPMD conference will be available on the Events & Presentations section of Capricor’s website after the conference.
CAP-2003 is being developed as a next-generation therapeutic platform in regenerative medicine. CAP-2003 is comprised of nano-scale extracellular vesicles, also referred to as exosomes, which exert anti-inflammatory, pro-angiogenic, anti-apoptotic, and anti-fibrotic effects. Exosomes contain bioactive molecules, including proteins, RNAs and microRNAs. They act as messengers to regulate the functions of neighboring cells. Pre-clinical research has shown that exogenously-administered exosomes can direct or, in some cases, re-direct cellular activity, supporting their therapeutic potential. Their size, ease of crossing cell membranes and ability to communicate in native cellular language make them an exciting class of potential therapeutic agents.
About Capricor Therapeutics
Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders. For more information, please visit www.capricor.com.
About the PPMD 2018 Annual Conference
The PPMD 2018 Annual Conference marks the 24th time families, physicians, researchers, caregivers, industry partners, and those living with Duchenne have gathered to discuss all topics Duchenne. It is hosted by PPMD, a nonprofit organization dedicated to the fight to end Duchenne. For more information, please visit: https://www.parentprojectmd.org/
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor’s product candidates; the initiation, conduct, size, timing and results of discovery efforts and clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including the ability to obtain regulatory approvals or otherwise bring products to market; plans regarding current and future collaborative activities and the ownership of commercial rights; scope, duration, validity and enforceability of intellectual property rights; future royalty streams, expectations with respect to the expected use of proceeds from the recently completed offerings and the anticipated effects of the offerings, and any other statements about Capricor’s management team’s future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “believes,” “plans,” “could,” “anticipates,” “expects,” “estimates,” “should,” “target,” “will,” “would” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor’s business is set forth in Capricor’s Annual Report on Form 10-K for the year ended December 31, 2017 as filed with the Securities and Exchange Commission on March 22, 2018, in its Registration Statement on Form S-3, as filed with the Securities and Exchange Commission on September 28, 2015, together with the prospectus included therein and prospectus supplements thereto and in its Quarterly Report on Form 10-Q for the quarter ended March 31, 2018, as filed with the Securities and Exchange Commission on May 14, 2018. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.
CAP-1002 is an Investigational New Drug and is not approved for any indications. CAP-2003 has not yet been approved for clinical investigation.
CONTACT: For more information, please contact: AJ Bergmann, Chief Financial Officer +1-310-358-3200 email@example.com